Skip to main content
Nicox S.A. logo

Nicox S.A. — Investor Relations & Filings

Ticker · COX ISIN · FR0013018124 LEI · 969500EZGEO9W4JXR353 PA Professional, scientific and technical activities
Open in API
Filings indexed 799 across all filing types
Latest filing 2025-12-16 Regulatory Filings
Country FR France
Listing PA COX

About Nicox S.A.

https://www.nicox.com/

Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutic solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox's pipeline is based on its proprietary NO-donating research platform. The company has also developed two approved ophthalmic products: VYZULTA® (latanoprostene bunod ophthalmic solution), licensed exclusively to Bausch + Lomb, and ZERVIATE® (cetirizine ophthalmic solution), licensed to various partners for commercialization.

Recent filings

Filing Released Lang Actions
Nicox Completes NCX 470 New Drug Application Key Data Generation for Submission as Planned in H1 2026
Regulatory Filings Classification · 1% confidence The document is a press release from Nicox SA announcing the completion of key data generation for a New Drug Application (NDA) for their product NCX 470. It details clinical milestones, future submission timelines, and corporate contact information. It does not constitute a formal financial report, audit, or regulatory filing, but rather a corporate update on operational progress. Given the nature of the announcement regarding business operations and development milestones, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2025-12-16 English
Nicox finalise la génération des données clés de demande d’autorisation de mise sur le marché de NCX 470 pour un dépôt maintenu au premier semestre 2026
Regulatory Filings Classification · 1% confidence The document is a press release from Nicox SA announcing the successful generation and analysis of clinical and stability data for its drug candidate NCX 470, in preparation for a New Drug Application (NDA) filing in 2026. It is a corporate announcement regarding business operations and regulatory progress, not a formal financial report, audit, or proxy statement. As it does not fit into specific categories like M&A or dividend announcements, it falls under the general regulatory filing/announcement category.
2025-12-16 French
Nicox : Résultats financiers du premier semestre 2025
Earnings Release Classification · 1% confidence The document is a press release titled 'Résultats financiers du premier semestre 2025' (Financial results for the first half of 2025) for Nicox SA. It contains key financial highlights, management commentary, and condensed financial statements (balance sheet and income statement) for the six-month period ending June 30, 2025. Since it provides comprehensive financial data for an interim period (half-year) rather than just a brief announcement of results, it is classified as an Interim/Quarterly Report. H1 2025
2025-10-23 French
Nicox Provides First Half 2025 Financial Results
Earnings Release Classification · 1% confidence The document is a press release titled 'Nicox Provides First Half 2025 Financial Results'. It contains key financial highlights, an income statement, and a balance sheet for the six-month period ending June 30, 2025. While it provides financial data, it is structured as a corporate press release rather than a formal, comprehensive interim report (which would typically be a longer, standalone regulatory filing). According to the 'Menu vs Meal' rule, this is an earnings release (ER) as it provides the initial announcement of quarterly/periodical financial results with key highlights. H1 2025
2025-10-23 English
Nicox annonce que NCX 470 a démontré une efficacité soutenue jusqu’à 12 mois dans l’essai clinique Denali, sans effets indésirables nouveaux observés
Earnings Release Classification · 1% confidence The document is a press release from Nicox SA announcing clinical trial results for their drug candidate NCX 470. It details the efficacy and safety findings from the Denali Phase 3 study. This type of corporate communication, which provides updates on business operations, clinical progress, and strategic milestones, is classified as a Regulatory Filing (RNS) as it does not fit into specific categories like earnings releases (financial results), investor presentations, or annual reports. Q4 2025
2025-10-02 French
Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations
Earnings Release Classification · 1% confidence The document is a press release from Nicox SA announcing the results of a clinical trial (Denali Phase 3). It provides key highlights of the trial's efficacy and safety data, mentions future milestones, and includes standard corporate boilerplate information. It does not constitute a full financial report, a regulatory filing, or a proxy statement, but rather serves as a general corporate announcement regarding operational/clinical progress. Given the lack of a more specific category for clinical trial results, it falls under the general regulatory announcement category. Q4 2025
2025-10-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.